-
Mashup Score: 5
The KRd regimen did not improve progression-free survival compared with the VRd regimen in patients with newly diagnosed multiple myeloma, and had more toxicity. The VRd triplet regimen remains the standard of care for induction therapy for patients with standard-risk and intermediate-risk newly diagnosed multiple myeloma, and is a suitable treatment backbone for the development of combinations of four drugs.
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5How Ireland beat the odds to introduce cancer warning labels on alcohol | WCRF International - 16 day(s) ago
Despite opposition from industry groups at home and internationally, Ireland will soon be the first country to warn drinkers of the links between cancer and any alcohol consumption on the drinks label. How did they do it?
Source: www.wcrf.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2
The device, which is used to temporarily support a patient’s heart, remains on the market in the US.
Source: www.bbc.co.ukCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Some nonprofit hospitals spend less on charity care than they receive in tax breaks, new analysis shows - 1 month(s) ago
A new study found 80% of 2,425 nonprofit hospitals spent less on charity care and community investment than they got in estimated tax breaks.
Source: www.statnews.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Some nonprofit hospitals spend less on charity care than they receive in tax breaks, new analysis shows - 1 month(s) ago
A new study found 80% of 2,425 nonprofit hospitals spent less on charity care and community investment than they got in estimated tax breaks.
Source: www.statnews.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Hospitals Are Adding Billions in ‘Facility’ Fees for Routine Care - 1 month(s) ago
Unsuspecting patients are finding themselves at the mercy of institutions tacking on the bills.
Source: www.wsj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Merck’s Keytruda Continues NSCLC Losing Streak with Phase III Flop - 1 month(s) ago
Keytruda, when used with AstraZeneca’s Lynparza, did not significantly improve overall and progression-free survival in specific patients with metastatic non-squamous non-small cell lung cancer.
Source: www.biospace.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1The Devil is in the Detail ! - 2 month(s) ago
https://twitter.com/MorphologyAmigo/status/1759940799062491480/photo/1
Source: morphologyamigo.substack.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5FDA Grants Accelerated Approval to Zanubrutinib Plus Obinutuzumab for Relapsed or Refractory Follicular Lymphoma - The ASCO Post - 2 month(s) ago
On March 7, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the small-molecule BTK inhibitor zanubrutinib (Brukinsa) in combination with the anti-CD20 monoclonal antibody obinutuzumab for patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. The regimen was evaluated in S tudy BGB-3111-212 (ROSEWOOD; ClinicalTrials.gov identifier NCT03332017), an open-label, multicenter, randomized trial that enrolled 217 adult patients with
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia - PubMed - 2 month(s) ago
Ruxolitinib was well tolerated and demonstrated an estimated response rate of 32%. Patients with a diagnosis of CNL and/or harboring CSF3R-T618I were most likely to respond.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
https://t.co/cEVbvEBI3F When will see data for 2 yrs vs Indefinite Len maintenance from this trial ? @VincentRK @ManniMD1 @RahulBanerjeeMD @Rfonsi1 @OncBrothers @Drjhoffmanmiami @rajshekharucms Tx related MDS/ AML is scary